113 results about "Dermatan sulfate" patented technology

The present invention provides peptide derivatives with a specific affinity for glycosaminoglycan molecules. These peptide derivatives include multimers as well as chemically modified peptides and may be prepared by a variety of methods. The peptides of the invention have numerous functions, including but not limited to use as inhibitors of glycosaminoglycan-mediated signaling events and targeting agents. Peptides of the invention may be directed against any glycosaminoglycan, including hyaluronic acid, chondroitin sulfate A, chondroitin sulfate C, dermatan sulfate, heparin, keratan sulfate, keratosulfate, chitin, chitosan 1, and chitosan 2. The peptide derivatives of the invention also have therapeutic uses in the treatment and prevention of diseases involving inflammatory diseases, cancer, and cancer metastasis, autoimmune diseases, etc.

The invention discloses a method for purifying dermatan sulfate from a heparin byproduct. The method comprises the following steps of: using the heparin byproduct as a raw material; dissolving the heparin byproduct, and then adding potassium acetate into the dissolved heparin byproduct; adjusting the pH value of solution by using acetic acid to generate a deposit, wherein clear solution is sulfate polysaccharide solution; adding a Ban's agent and saturated sodium hydroxide solution into the sulfate polysaccharide solution; centrifugally collecting the deposit; performing re-precipitation; dissolving the deposit again; washing away copper ions by using a chromatography column with anion exchange properties and sodium chloride solution; performing linear gradient elution by using the sodium chloride solution; collecting eluant; and evaporating and concentrating the eluant, and depositing the eluant by using ethanol to obtain high-purity dermatan sulfate. The method has the advantages of simple purification process, high purification yield, low cost, easy amplification and suitability for industrial production.

Compositions and methods are provided for treating joint conditions, such as osteoarthritis and/or the pain associated therewith. The compositions and methods utilize a first component, namely hyaluronic acid (“HA”), in combination with at least one stabilizer. The composition can include a stabilizer that increases the stability and shelf-life of the HA. In another embodiment, the compositions and methods can also include an additional component, such as one or more glycosaminoglycans (“GAG”) or GAG precursors. Examples of GAGs or GAG precursors can include chondroitin sulfate (“CS”), dermatan sulfate, heparin, heparan sulfate, keratan sulfate, and glucosamine (“GlcN”).

Compositions and methods are provided for treating joint conditions, such as osteoarthritis and/or the pain associated therewith. The compositions and methods utilize a first component, namely hyaluraonic acid (“HA”), in combination with a lyophilized second component that is effective to at least temporarily reduce the viscosity of the HA. In an exemplary embodiment, the second component is one or more glycosaminoglycans (“GAG”), such as chondroitin sulfate (“CS”), including CS4 and/or CS6, dermatan sulfate, heparin, heparan sulfate, and keratan sulfate. The composition can optionally include other joint supplements, such as glucosamine (“GlcN”)

It is concerned with extraction and purification of sulfuric acid skin-lotion from waste skins of angler fish production. It is carried out by: extracting with compounded enzyme of pancreatin and papain, adding NaOH into extracting liquid to cut off glycopeptide bond while protecting glycosidic bond with NaPH4, removing protein by savage process, depositing sulfur acid skin lotion in alcohol, dissolving in water and centrifuging dissoluble substances, dialyzing to remove ions and micro-molecular substances, and frozen drying high purity sulfur acid skin lotion with ratio of sulfate radical to carboxylic radical = 1.07. The product is strong antithrombotic, with less side effect of hemorrhage, has disinfecting activity, and can be used in pharmaceutical field.

Co-incubation of an amyloid protein with sulfated macromolecules as a method for the formation of amyloid plaques. The amyloid protein may be the beta-amyloid protein or the prion protein or the like. Amyoid plaque formation in one embodiment proceeds in vitro and desireably produces amyloid plaques that stain with Congo red and demonstrate a maltese-cross pattern when viewed under polarized light. The method also produces amyloid plaques that demonstrate an "amyloid star" appearance when viewed by transmission electron microscopy. Sulfated macromolecules include a sulfated proteoglycan selected from the group consisting of perlecan, ~220 kilodalton heparan sulfate proteoglyean, glypican, cerebroglycan, aggrecan, synaptoglycan (SV2PG), syndecan, N-syndecan (also known as syndecan-3), syndecan-1, syndecan-4, neurocan, phosphacan, decorin, biglycan, versican, amphiglycan, lumican, PG-M, PG-M (3), agrin, betaglycan, claustrin, brevican, appican, epican, neuroglycan-C, and fragments thereof. Thw sulfated macromolecule may be a sulfated glycosaminoglycan selected from the group consisting of heparin, heparan sulfate, dermatan sulfate, chondroitin sulfate, keratan sulfate, and fragments thereof. An in vivo assay is also presented for selecting a candidate therapeutic agent for inhibiting or disrupting amyloid plaque deposition or persistence. The assay includes a) pre-forming congophilic maltese-cross amyloid plaques in vitro following incubation of an amyloid protein and a selected sulfated macromolecule, b) using a first cannula and osmotic pump to continuously infuse for a selected duration the pre-formed congophilic maltese-cross amyloid plaques into a tissue or organ, c) changing the first cannulae and osmotic pump with a second cannulae and osmotic pump to administer the candidate therapeutic, and d) detecting the candidate therapeutic's ability to disrupt, reduce, or eliminate congophilic maltese-cross amyloid plaque deposition/persistence in the tissue or organ.

The invention relates to inscribe chondroitin sulfate/dermatan sulfate 4-O-sulfatase as well as an encoding gene and an application of the inscribe chondroitin sulfate/dermatan sulfate 4-O-sulfatase. The invention firstly discloses an amino acid sequence of the inscribe chondroitin sulfate/dermatan sulfate 4-O-sulfatase and a nucleotide sequence of the encoding gene of the inscribe chondroitin sulfate/dermatan sulfate 4-O-sulfatase. Found through detection, the enzyme has relatively high inscribe sulfatase activity, plays a role in removing sulfate radicals at the terminal and the inside of polysaccharide and can be effectively acted on polysaccharide, used for modifying and regulating the structure inside polysaccharide and applied to preparation of drugs for restoring cranial nerve involvement, regulating metabolism and treating inflammation and cancer.

The invention discloses a chondroitin sulfate/dermatan sulfate extraction method which comprises the following steps: drying the eggshell matrix and grinding to obtain eggshell matrix powder; separating and extracting total glycosaminoglycan from the eggshell matrix powder; and removing heparin/heparan sulfate, keratan sulfate and hyaluronic acid in the total glycosaminoglycan to obtain high-purity chondroitin sulfate/dermatan sulfate.

The invention belongs to the technical field of biology and particularly relates to a method for removing keratan sulfate from a chondroitin sulfate crude extract. The method comprises the following steps of adding a sodium hydroxide solution into a chondroitin sulfate crude extract for reaction; then adding hydrochloric acid to regulate the PH value, filtering to obtain a filtrate, and adding sodium chloride into the filtrate to regulate the electrical conductivity of the solution to be 45-48ms/cm; then adding an ethanol solution, controlling the flow velocity of the ethanol solution to be 10-15mL/(L.min), precipitating chondroitin sulfate, and filtering to obtain a precipitate; dehydrating and drying the precipitate obtain a chondroitin sulfate finished product. The method is easy in control over technological conditions, low in cost, simple in operation and low in experimental apparatus requirement, and can be used for thoroughly solving the problems that removal of the keratan sulfate in chondroitin sulfate is difficult and industrial production is difficult to realize.

The invention provides a process of producing heparan sulfate by using chondrosulphatase. The process comprises the following steps: firstly, performing enzymolysis, resin adsorption and sodium chloride solution elution on a heparin sodium crude product to obtain eluate; performing enzymolysis on the eluate by using chondrosulphatase ABC or chondrosulphatase B; exclusively cutting off specificity of 1-4 glucosidic bonds between disaccharide units in a dermatan sulfate structure by virtue of the chondrosulphatase ABC and the chondrosulphatase B to obtain a degradation reaction product unsaturated disaccharide; and then, performing refining steps such as ultrafiltration, heavy metal removal and oxidization to obtain a heparan sulfate fine product. The process not only can be used for overcoming the characteristic that negative charges on the surfaces of the heparan sulfate and the dermatan sulfate are similar in density and difficult to separate, but also can be used for avoiding heavy metal ion impurities brought in heparan sulfate produced according to the conventional route, and thus, the product yield is increased, and the economic benefits are remarkable.

A low-molecular (3000-8000) dermatan sulfate is prepared from the dermatan sulfate through degradation by hydrogen peroxide, ultrafilter, and gel chromatography. Its advantages are sure thrombus-resistant and thrombolytic functions, easy absorption, long semi-life and high biologic utilization rate.

The invention discloses a method of preparing high-purity heparin sodium. The method is characterized in that under a room temperature of 298K, an organic precipitation method is adopted to remove heparin sodium-like impurities dermatan sulfate and chondroitin sulfate in the heparin sodium to prepare high-purity heparin sodium, so that the heparin sodium and similar substances thereof are separated according to solubility difference in different polar solvents. The method is suitable for purifying and separating the sodium-like impurities dermatan sulfate, chondroitin sulfate and the like in the heparin sodium to prepare the high-purity heparin sodium, and has remarkable social and beneficial benefits.